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INTRODUCTION
Equine herpesvirus type 1 (EHV1), a member of the
Alphaherpesvirinae, is endemic in the horse population
worldwide. After infection, the virus replicates in tis-
sues of the upper respiratory tract. Primary replication
is followed by a leukocyte-associated viremia that ena-
bles EHV1 to reach internal organs (Gryspeerdt et al.,
2009; Kydd et al., 1994a, b). A second replication in
endothelial cells at the site of the pregnant uterus may
result in abortion and neonatal foal death, and a second
replication in the nervous system may result in nervous
system disorders (Allen and Bryans, 1986; Gilkerson
and Barrett, 2008). The form in the nervous system,
which is also designated as equine herpes myelitis
(EHM), is a severe condition that is still poorly under-
stood, despite the correlation between a single amino
acid variation in the ORF30 region of the viral DNA
polymerase and neurological disease (Lunn et al.,
2009; Van de Walle et al., 2009). 
EHV1 is a ubiquitous pathogen that has a world-
wide distribution and is responsible for widespread
annual problems with respiratory disorders and abor-
tion. In contrast, outbreaks of nervous system dis-
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ABSTRACT
Neurological diseases caused by neuropathogenic strains of EHV1 are being reported with increasing
frequency. Consequently, concern is being voiced within the US horse industry that the neurologic form of
EHV1 may be intensifying in prevalence and/or morbidity and mortality. In Belgium, outbreaks of EHV1-
induced abortions are an annually recurrent phenomenon, but outbreaks of equine herpes myelitis (EHM) are
rare. This report describes an unusually large outbreak of EHV1-induced EHM that involved at least 13
different premises. Seven of them were characterized in more detail and were included in this study. A
morbidity of 26% was seen, with an EHM incidence of 43% in the affected horses. The outbreak was
characterized by rapid occurrence of ataxia and paralysis immediately after disappearance of the fever. EHV1
was diagnosed by means of virus isolation and/or seroconversion. The isolated virus was classified either as
neuropathogenic or as belonging to group 4 after sequencing in the ORF30 and ORF68 regions, respectively.
The extent of this outbreak and the high percentage of neurological disease, along with the fact that EHM
is only sporadically seen in Belgium, might indicate that the neurological form of EHV1 is possibly also
emerging in Belgium.
SAMENVATTING
Zenuwstoornissen veroorzaakt door neuropathogene stammen van EHV1 worden met stijgende frequentie
waargenomen. In de paardenindustrie van de Verenigde Staten is bezorgdheid geuit omtrent het feit dat de prevalentie
van de neurologische vorm van EHV1, evenals de morbiditeit en mortaliteit, aan het toenemen zijn. Uitbraken van
door EHV1-geïnduceerde abortus worden in België jaarlijks waargenomen, maar uitbraken van equiene herpes
myelitis (EHM) zijn zeldzaam. In dit artikel wordt een ongewoon grote uitbraak van EHV1-geïnduceerde EHM
beschreven, waarbij tenminste 13 bedrijven betrokken waren. Zeven van hen werden in meer detail onderzocht en
werden in voorliggend onderzoek ingesloten. Er werd een morbiditeit gezien van 26%, met een EHM-incidentie van
43% bij de aangetaste paarden. De uitbraak werd gekarakteriseerd door het snel optreden van ataxie en paralyse
onmiddellijk na het verdwijnen van de koorts. EHV1 werd gediagnosticeerd door middel van virusisolatie en/of
seroconversie. Het geïsoleerde virus werd geclassificeerd als neuropathogeen en behorende tot groep 4 na sequenering
in de ORF30- en ORF68-regio respectievelijk. 
De omvang van deze uitbraak en het hoge percentage neurologische ziekte, samen met het feit dat EHM slechts
sporadisch wordt gezien in België, kunnen erop wijzen dat de neurologische vorm van EHV1 ook in opmars is in
België.
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orders caused by infection with EHV1 seem to be
more rare. However, during the last decade, large out-
breaks of EHM have been reported in the USA with in-
creasing frequency, and the rate of fatal outcomes af-
ter substantial suffering also appear to be on the rise
(Lunn et al., 2009). EHV1 is also endemic in the horse
population in Belgium, with EHV1-induced abortion as
an annually recurrent event. However, EHM is rare and
mostly involves a limited number of horses on a single
premise (van der Meulen et al., 2000). To date, only
one description of EHV1-induced neurological dis-
orders has been reported in Belgium. No extensive
spread of EHM was seen during this episode and severe
disease was limited to the affected premise. The signs
in neurologically affected horses consisted mainly of
ataxia and paralysis, but cerebral dysfunctions were
also noted (van der Meulen et al., 2003).
The present report describes a large outbreak of
EHV1-induced neurological disease in Flanders in 2009
that started on a riding school and spread to at least 12
premises that had been in direct contact with the riding
school. The extent of this outbreak, along with the
higher percentage of horses with neurological signs,
but without the occurrence of cerebral dysfunction, and
the rapid occurrence of severe signs, raises the intriguing
question as to whether EHM is also emerging in Bel-
gium. 
MATERIALS AND METHODS
Description of the premises 
During an outbreak of EHV1-induced nervous sys-
tem disorders in Antwerp, Belgium (June 2009), fever
and neurological disease were observed on at least 13
premises. All these premises had attended a jumping
contest on May 30th, 2009, at a riding school (premise
no. 1) where the first cases of neurological signs oc-
curred. Although 13 premises reported neurological di-
sease, only the data from 7 of these premises has been
included in this report. On these premises, EHV1 in-
fection was confirmed by virus isolation and/or sero-
conversion (Table 1). The other 6 affected premises had
several horses with neurological problems, but refused
to give any further information and were therefore not
included in this study (Figure 1). Information about
vaccination state, management and housing can be
found in Figure 1 and Table 2. Each premise was visi-
ted to evaluate the clinical signs, and local veterinarians
were asked to collect blood samples from the horses sus-
pected of infection with EHV1, both for the purpose of
virus isolation from leucocytes and for the detection of
seroconversion in paired serum samples. 
Serological examination
The presence of EHV-specific antibodies was de-
termined with a complement-dependent seroneutrali-
zation (SN) test in acute serum samples and in conva-
lescent serum samples three weeks later. Two-fold
dilution series of the sera were prepared in MEM.
Fifty µl of each of these serial dilutions was incubated
for 23 hours (h) at 37°C with a fixed number of infec-
tious virus (300 TCID50 of EHV1 strain Arabica in 50
μl). Thereafter, 25 µl of guinea pig complement was
added. After 1 h of incubation, the mixture of serum,
virus and complement was added to RK13 cells. The
inoculated cultures were further incubated at 37°C in
an atmosphere containing 5% CO2. After 7 days of in-
cubation, the cultures were analyzed for the presence
of cytopathic effect. The neutralization titer was cal-
culated as the reciprocal of the highest dilution of se-
rum that was able to completely block EHV1 infection
in RK13 cells. Seroconversion was present when the
antibody titer of the convalescent sample was at least
four times higher than in the acute sample.
Table 1. Results from different diagnostic tools to confirm EHV1 infection in discussed horses.
Premise Horse Signs Isolation Antibody titer in serum
at the of EHV1 from
moment PBMC Acute sample Convalescent
of sampling Isolation  sample
1 1 fever + 128 1536
2 quadriplegia + 64 NA
2 1 fever + 48 512
2 fever + 16 256
3 1 ataxia + 192 512
2 ataxia + 96 1024
3 ataxia - 16 256
4 1 quadriplegia + 96 NA
5 1 fever + 4 1536
2 fever + 12 768
3 fever - 8 1024
4 fever + 12 2048
6 1 ataxia + 32 1536
7 1 ataxia + 4 1536
2 ataxia - 8 1536
NA: not available due to euthanasia
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Virological examination
Virus isolation from peripheral blood mononuclear
cells (PBMC) was performed on RK13 cells. Unclot-
ted blood samples were taken from horses with clini-
cal signs (fever and/or neurological disorders). PBMC
were isolated by means of density centrifugation on Fi-
coll-Paque (Pharmacia Biotech AB, Uppsala, Sweden)
and subsequently inoculated on monolayers of RK13
cells. These monolayers were incubated at 37°C in an
atmosphere containing 5% CO2 and examined daily
for 7 consecutive days for the presence of cytopathic
effects.
PCR amplification and sequencing of ORF30 and
ORF68
DNA was extracted from EHV1 isolates using a
QiaAmp DNA extraction kit (Qiagen Benelux, Venlo,
The Netherlands). Amplification of ORF30 was per-
formed using the primers ORF30fw (gctacttctgaa-
aacggaggc) and ORF30rev (ctatcctcagacacggcaaca).
Amplification of ORF68 was performed using either
the primer  ORF68atg1 (atgggtgtggtcttaattac) or the pri-
mer ORF68fw (aagcattgccaaacagttcc), in either case in
combination with ORF68end1 (aacgtgtggatgtccggcc). 
The PCR products were treated with Exonuclease
I and Antarctic Phosphatase (New England Biolabs,
Ipswich, USA) and used directly for cycle sequencing
with a Big Dye Terminator Cycle sequencing kit V1.1
(Applied Biosystems, Foster City, USA). Additional in-
ternal oligonucleotides were used for the sequencing of
ORF68. The cycle sequencing reaction products were
purified using ethanol precipitation and separated on an
ABI Genetic Analyzer 310 (Applied Biosystems, Fos-
ter City, USA). The sequences were analyzed and com-
piled using Align, ClustalW and Sixframe in the work-
bench (workbench.sdsc.edu) and BlastN and BlastP at
www.ncbi.nlm.nih.gov. To validate the sequencing,
previously characterized strains 97P70 (Genbank ac-
cession number: GU271940), 03P37 (# GU271941)
and Ab4 (# AY665713) were included (Garré et al.,
2007; Nugent et al., 2006).
RESULTS
Case history (Figure 1 and Table 2)
Initial outbreak
In May and June of 2009 an outbreak of EHV1 oc-
curred in a riding school with 96 horses. This premise
(premise no. 1) was a riding school where lessons and
contests took place frequently and from where horses
Figure 1. Schematic overview of the course of the outbreak of EHV1-induced neurological disorders on the different
premises. NSD: nervous system disorders; open management: public riding school with incoming and outgoing horses;
half-open management: private premise, but where horses attend competitions at other premises; closed management:
private premise, no contact with other horses or premises; housing with direct contact: stables separated from each other
by bars; housing with indirect contact: stables separated from each other by full walls.
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were regularly transported to contests outside the pre-
mise. 
On May 14, the local practitioner was consulted for
a 5-year-old mare with high fever. The mare was trea-
ted with antibiotics and the fever lasted for 4 days
without any further signs. On May 26, another mare
(age 20) was presented with high fever. She was also
treated with antibiotics. On the fifth day, the fever cea-
sed but the mare was found recumbent in her stable.
Since at that point in time there was no suspicion of
EHV1-induced neurological disease, a large contest
was organized at this riding school, with horses from
different premises. On June 1st, two additional mares (9
and 12 years) on premise no. 1 showed fever as well as
edema of the hind limbs. The fever lasted for 5 and 3
days, respectively, and no other clinical signs were
noted. On June 5, a 9-year-old mare showed fever las-
ting for 4 days, after which she became severely ataxic
and then, shortly thereafter, completely paralyzed. The
next day, eight more horses showed high fever, five of
which (one mare and four geldings between 4 and 14
years) became clinically normal after a 2-3 day period
of fever. One mare (12 years), however, showed para-
lysis after 3 days of fever. Two other horses showed
neurological signs after 5 days of fever. The first horse
was a 12-year-old mare that was found with hind leg
paralysis. The second horse, a gelding of 12 years,
was severely ataxic, being barely able to stand up and
showedsevere muscle trembling. On June 7, two other
mares (8 and 12 years) developed signs. The first mare
developed severe ataxia without preceding fever, and
the second mare developed a fever that lasted for three
days without further signs. On June 8, a 12-year-old
gelding became febrile for 7 days, but no further signs
developed. All the horses with severe neurological dis-
orders were euthanized and, since EHV1 was suspec-
ted as the etiological agent, the riding school was com-
pletely shut down at this time. On June 9, a mare (11
years) showed an elevated body temperature for 4 days
and a 13-year-old gelding was found to be slightly
ataxic without preceding fever. On June 11, an 8-year-
old mare suddenly became severely ataxic, without a
preceding febrile period, and this condition quickly
evolved to complete paralysis. At that time, the Faculty
of Veterinary Medicine was contacted for an etiologi-
cal diagnosis, whereby EHV1 was isolated from the
PBMC from this horse, thus confirming the suspicion
of a severe outbreak of EHV1. The last affected horse,
presented on June 16, was a 4-year-old gelding with fe-
ver for 5 days, followed by urticaria and muscle tre-
mors. EHV1 was confirmed by virus isolation and the
horse was treated with the antiviral drug valacyclovir
(Garré et al., 2009). As the muscle tremors stopped the
next day and no other signs of EHV1 infection were
observed, the therapy was stopped after 2 days.
Secondary outbreaks
From June 5 till June 28, several premises reported
neurological disease after attending the jumping con-
test on premise no. 1. On premise no. 2, a 6-year-old
mare developed fever on June 5 and showed severe pa-
ralysis after 3 days of fever. Fifteen days later, two
other horses (a 13-year-old mare and an 8-year-old
gelding) showed fever for 3 consecutive days, without
developing any other signs.
On premise no. 3, two mares (8 and 5 years) that
had attended the competition became slightly ataxic
without preceding fever, on June 9. One day later, a
third mare (10 years) showed weakness for 1 day but
became clinically normal afterwards. On premise n° 4,
two mares showed a slightly elevated body temperature
on June 9. Seven days later, two mares and two gel-
dings showed fever for 2 or 3 days. On June 19, a 7-
year-old mare was found quadriplegic after 3 days of
fever and was treated with valacyclovir 1.5 days later.
The first 2 days after the treatment was initiated, the
mare showed good clinical improvement. She was
able to stand and to move around with the support of
a sling. After 3 days, however, treatment was stopped
due to a lack of available valacyclovir. The mare re-
mained clinically stable for several days, but no further
improvement of clinical signs was observed. Two
weeks after the onset of neurological signs, she was
able to stand in the sling and started to regain bladder
control, but was not able to lie in sternal position or to
stand up on her own. Because this caused severe an-
xiety for the horse, she was eventually euthanized. On
premise n° 5, a 9-year-old mare became slightly ataxic
on June 9. On the same day, another horse (10 years)
showed weakness in the limbs. Also starting on June 9,
a 5-year-old gelding had elevated temperatures for 3
days and was weak. Three days later, the remaining
four horses of premise no. 5 showed high fever for se-
veral days. Two of these horses (both mares, 7 and 5
years old) became quadriplegic after 2 days. These
two mares were treated with valacyclovir at the onset
of nervous system disorders. The first mare was hung
in a sling and showed rapid improvement, so the treat-
ment was stopped 5 days later. The second mare was
treated for 3 consecutive days, with rapid improvement
during the treatment, but with no further improvement
once the treatment was stopped. 
On June 15, premise no. 6 reported affected horses,
starting with a 10-year-old mare that had attended the
jumping contest. She became anorectic and febrile for
3 days, after which she became slightly ataxic. An 11-
year-old gelding became severely ataxic after 3 days of
fever. Four days later, a gelding (6 years) showed fe-
ver for 2 days, but did not develop any other signs. 
Finally, on June 17 on premise no. 7, two horses (a
gelding of 16 years and a mare of 11 years) that had at-
tended the contest developed a high fever for 3 days.
After the fever had subsided, the two horses became se-
verely ataxic. Two days later, a 5-year-old mare deve-
loped slight ataxia. The other eight horses on the pre-
mise developed high temperatures over the course of
several days, but no neurological disorders were noted. 
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Virology and serology
Blood samples were collected from seven horses
with high fever, six horses with ataxia and two horses
with quadriplegia at the moment of sampling (Table 1).
EHV1 was isolated by means of PBMC co-cultivation
from six of the seven horses with high fever (86%), from
four of the six horses with ataxia (67%) and from the
two horses with quadriplegia (100%) (Table 1). Sero-
conversion of EHV-specific antibodies was evaluated
for thirteen of the fifteen horses, both at the time when
the clinical signs appeared (acute sample) and three
weeks later (convalescent sample). Twelve horses sero-
converted for EHV1 (Table 1). 
All EHV1 isolates were typed as neuropathogenic
by sequencing of the D752 allele in the ORF30 region
(e.g. 09P240, # GU271939). In addition, all the viru-
ses were sequenced in their ORF68 region, a genetic
marker for grouping isolates into six major geogra-
phically restricted groups (Nugent et al., 2006). All the
isolates in this outbreak of neurological disease be-
longed to group 4. These genetic analyses, along with
the direct link between the confirmed premises and pre-
mise no. 1, further confirmed the assumption that all
EHV1 infections on the different premises were caused
by the same virus spread from premise no. 1.
DISCUSSION
The present paper reports a large outbreak of
EHV1-induced neurological disease in Antwerp, Bel-
gium in June 2009. How this epidemic started is not
known. However, two weeks before the first horse be-
came recumbent, a 5-year-old mare was presented with
fever, and it could be hypothesized that this mare either
reactivated latent EHV1 or got infected with EHV1 due
to the many contacts with visiting horses on the pre-
mise. Secondary outbreaks on other premises occurred
as a consequence of direct contact with infected horses
from the first premise. Both the first premise and the se-
condarily affected premises were quarantined for three
weeks and all the horses in the neighborhood that were
without clinical signs were vaccinated. The outbreak
was successfully controlled due to management, qua-
rantine and vaccination measures, and one month after
the onset of the outbreak, no more cases of EHV1 in-
fection were diagnosed. During this large outbreak, se-
veral interesting observations were made.
Firstly, the morbidity rates were lower (7 to 21%)
on the vaccinated premises (no. 1 and 4) compared to
the non-vaccinated premises (25 to 100%) (Figure 1).
On premise no. 4, where both vaccinated and unvac-
cinated horses were present, fever and neurological di-
sease were only reported in the unvaccinated horses,
whereas the vaccinated horses showed no clinical signs
of EHV1 infection. A similar observation was made du-
ring other outbreaks of EHM, most of which occurred
on premises with unvaccinated horses (Goehring et al.,
2006; van der Meulen et al., 2003). This could indicate
that vaccinated horses have clinical protection against
severe symptoms of EHV1. Whether this protection is
the result of the reduced spread of the virus or of a vi-
rological effect is not clear. Interestingly, although lo-
wer morbidity rates were observed on vaccinated pre-
mises no. 1 and no. 4, no difference could be seen in the
number of horses that eventually developed nervous
system disorders compared to the non-vaccinated pre-
mises (Table 2). In Belgium, only inactivated vaccines
are registered for use in horses. These vaccines mainly
stimulate humoral immunity, whereas it has been sug-
gested that cell-mediated immunity is of paramount im-
portance for limiting EHV1 infection (Kydd et al.,
2006; Kydd et al., 2003).
Secondly, four horses were treated orally with the
antiviral drug valacyclovir during this outbreak. Ex-
perimental in vivo studies to evaluate the efficacy of
this drug in reducing clinical signs, viral shedding,
and viremia have been performed, but with contradic-
tory results (Garré et al., 2009; Maxwell et al., 2008).
Although during the present outbreak the treated horses
tended to recover more rapid as compared to untreated
horses with similar clinical features, it remains difficult
to evaluate the benefits of valacyclovir treatment du-
ring this outbreak due to the limited number of treated
horses versus non-treated horses and the variable treat-
ment periods.
Thirdly, during the current outbreak, equal numbers
of male and female horses were exposed to EHV1 and
became infected (Table 2), thus indicating no influence
of gender on EHV1 susceptibility. In contrast, however,
Table 2. Description of the animals on the premises with EHV1 associated neurological disorders.
Premise Total n° Total n° of affected N° of horses with
N° of horses present horses neurological disorders
Male Female Total Male Female Total (%) Male Female Total (%)
1 53 43 96 8 12 20 (21%) 2 6 8 (40%)
2 1 2 3 1 2 3 (100%) 0 1 1 (30%)
3 2 10 12 0 3 3 (25%) 0 3 3 (100%)
4 42 38 80 2 5 7 (9%) 0 1 1 (14%)
5 3 4 7 3 4 7 (100%) 1 4 5 (71%)
6 2 1 3 2 1 3 (100%) 1 1 2 (67%)
7 5 6 11 5 6 11 (100%) 1 2 3 (27%)
108 104 212 21 33 54 (26%) 5 18 23 (43%)
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we did observe that once infected, the mares appeared
to be predisposed to developing severe ataxia and pa-
ralysis. Indeed, 55% (18/33) of the infected mares de-
veloped nervous system disorders, whereas this was
only 24% (5/21) for the infected male horses (Table 2).
The higher sensitivity of mares to developing severe
neurological signs during EHV1 infection has previ-
ously been described (Goehring et al., 2006; McCar-
tan et al., 1995), but so far, no explanation for this ob-
servation has been found. 
Finally, both virus isolation from peripheral blood
mononuclear cells (PBMC) and seroconversion were
used to diagnose EHV1 during this outbreak. More-
over, EHV1 was successfully isolated from PBMC
during this outbreak. This is in contrast to previous pu-
blished studies, which mention that virus isolation
from PBMC in outbreak situations can be problematic
(Lunn et al., 2009; van Maanen et al., 2001). In addi-
tion, seroconversion has also been reported to have li-
mitations in confirming a diagnosis of EHV1, especi-
ally in horses with neurological signs (Lunn et al.,
2009). Interestingly, during the outbreak in the present
study, all the horses with neurological disorders sero-
converted, with the exception of one horse. One ex-
planation for the successful diagnosis during this out-
break could be the rapid occurrence of severe signs
during the outbreak, which increased the chances of de-
tecting infectious virus and seroconversion. The low
initial levels of EHV1 antibodies in a largely unvacci-
nated population could also have contributed to the
easy detection of seroconversion.
During the only other reported outbreak of EHV1-
induced neurological disease in Belgium, which oc-
curred six years ago, a morbidity of 42% was seen,
with 15% of the horses showing neurological dis-
orders. Ataxia and paralysis were observed, but also
cerebral disorders such as blindness, torticollis and se-
vere apathy (van der Meulen et al., 2003). During the
recent outbreak, cerebral disorders were not observed,
but interestingly, the outbreak was characterized by the
rapid onset of ataxia and paralysis immediately after
the disappearance of fever. In addition, the incidence
of neurological signs in the EHV1-affected horses
was much higher in the recent outbreak (43%) com-
pared to the outbreak in 2003 (15%) (van der Meulen
et al., 2003). These observations might possibly point
towards a change in neuropathogenic potential of na-
turally circulating EHV1 strains.
During the preparation of this manuscript, two new
unrelated outbreaks of EHV1-induced EHM were re-
ported and diagnosed. These outbreaks occurred in
June 2010 and will be summarized briefly. The first af-
fected premise had a half-open management system
without any vaccination protocol. One mare had been
transported from the premise to a breeding facility
where problems of high fever and edema of the limbs
were then being observed. When the mare was brought
back, she was showing the same symptoms, and the vi-
rus then spread to the 5 other horses on the home pre-
mise (6 in total). Two of these horses were euthanized
due to severe paralysis, three showed severe ataxia,
which stabilized upon valacyclovir treatment, and one
of them aborted at 10.5 months of gestation. EHV1 was
isolated from PBMC from all 6 of the horses and was
typed neuropathogenic by sequencing in the ORF30 re-
gion. The second outbreak occurred on a premise with
an open management system and a once-a-year vacci-
nation protocol.  Here too, several horses showed high
fever and edema of the limbs. One mare on this pre-
mise, which had not been given the yearly vaccination,
showed severe ataxia and EHV1 was isolated and sub-
sequently typed as non-neuropathogenic. 
In summary, concern has been voiced within the
U.S. horse industry that the neurologic form of EHV1
might be emerging, based on the increasing numbers of
EHM outbreaks and the growing numbers of seriously
affected horses throughout the United States over the
last decade (USDA, 2007). Up until the recent out-
break, no such evolution had been seen in Belgium and
no reports of EHM outbreaks had been reported, with
the exception of the single limited outbreak in 2003.
The present report describes this recent, large outbreak
of EHV1, with its rapid spread and the remarkably high
numbers of animals suffering from EHM. This, toge-
ther with the fact that in 2010 two other small outbreaks
were also reported, raises the question as to whether the
neurological form of EHV1 is also emerging in Bel-
gium and hence Europe. However, it is not clear whe-
ther these observations are related to the possible in-
creasing occurrence and virulence of the disease itself,
or to the increasing awareness of the disease and the
development of increasingly effective diagnostic me-
thods (USDA, 2007). Many data gaps exist, and more
investigations need to be conducted to better under-
stand this evolving situation and to identify other pos-
sible factors that may be playing a role. It is for this rea-
son that a good surveillance system in Belgium and
Europe is needed to monitor outbreaks of EHM, to ac-
quire better understanding of the virulence of naturally
circulating EHV1 strains and to determine whether
EHM is in fact an emerging disease.
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